$454 Million is the total value of Sarissa Capital Management LP's 16 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 17.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ABBV | ABBVIE INC. | $90,249,000 | -3.6% | 1,580,000 | 0.0% | 19.89% | +9.3% | |
| ARIA | ARIAD PHARMACEUTICALS INC | $82,111,000 | +2.2% | 12,850,000 | 0.0% | 18.09% | +15.9% | |
| BIIB | BIOGEN INC | $80,699,000 | -15.0% | 310,000 | 0.0% | 17.78% | -3.7% | |
| MDCO | Buy | MEDICINES CO | $55,661,000 | -4.9% | 1,752,000 | +11.8% | 12.26% | +7.8% |
| DGX | QUEST DIAGNOSTICS INC | $41,083,000 | +0.4% | 575,000 | 0.0% | 9.05% | +13.8% | |
| PCRX | PACIRA PHARMACEUTICALS INC | $28,195,000 | -31.0% | 532,200 | 0.0% | 6.21% | -21.8% | |
| ITCI | INTRA CELLULAR THERAPIES INC | $18,764,000 | -48.3% | 675,000 | 0.0% | 4.14% | -41.4% | |
| RPTP | New | RAPTOR PHARMACEUTICAL CORP | $12,535,000 | – | 2,725,000 | +100.0% | 2.76% | – |
| ESPR | Buy | ESPERION THERAPEUTICS INC NE | $10,704,000 | +7.3% | 633,000 | +41.3% | 2.36% | +21.7% |
| AEGR | AEGERION PHARMACEUTICALS INC | $9,546,000 | -63.4% | 2,580,000 | 0.0% | 2.10% | -58.5% | |
| ARRY | Buy | ARRAY BIOPHARMA INC | $8,481,000 | +187.1% | 2,875,000 | +310.7% | 1.87% | +225.6% |
| APRI | Buy | APRICUS BIOSCIENCES INC | $8,412,000 | +30.2% | 14,479,052 | +121.9% | 1.85% | +47.6% |
| VVUS | VIVUS INC | $3,603,000 | +37.3% | 2,573,943 | 0.0% | 0.79% | +55.7% | |
| AVEO | AVEO PHARMACEUTICALS INC | $2,128,000 | -27.0% | 2,313,759 | 0.0% | 0.47% | -17.3% | |
| RPRX | REPROS THERAPEUTICS INC | $970,000 | -19.9% | 1,001,000 | 0.0% | 0.21% | -8.9% | |
| TARGACEPT INCnote 2/1 | $680,000 | 0.0% | 680,399 | 0.0% | 0.15% | +13.6% | ||
| ANIP | Exit | ANI PHARMACEUTICALS INC | $0 | – | -31,000 | -100.0% | -0.27% | – |
| AMGN | Exit | AMGEN INC | $0 | – | -90,000 | -100.0% | -2.84% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.